Agenus Inc. (AGEN)
NASDAQ: AGEN
· Real-Time Price · USD
4.45
-0.03 (-0.67%)
At close: Sep 15, 2025, 3:59 PM
4.49
0.89%
After-hours: Sep 15, 2025, 07:17 PM EDT
-0.67% (1D)
| Bid | 4.35 |
| Market Cap | 141.8M |
| Revenue (ttm) | 101.71M |
| Net Income (ttm) | -165.52M |
| EPS (ttm) | -7.06 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -3.36 |
| Analyst | Hold |
| Ask | 4.56 |
| Volume | 239,415 |
| Avg. Volume (20D) | 876,616 |
| Open | 4.49 |
| Previous Close | 4.48 |
| Day's Range | 4.36 - 4.50 |
| 52-Week Range | 1.38 - 7.34 |
| Beta | 1.44 |
About AGEN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AGEN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Agenus Inc. is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+19.26%
Agenus shares are trading higher after partner MiN...
Unlock content with
Pro Subscription
3 months ago
+12.6%
Agenus shares are trading higher after HC Wainwright & Co. and Baird raised their respective price targets on the stock.
1 month ago · businesswire.com
Agenus to Provide Corporate Update and Second Quarter 2025 Financial ReportLEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before th...
